| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2cfbc5912794c75a2d32b6968113facb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1abc822a98985bf0ab7c77f8849ceaa5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_990b574dc9a0c2c4f5a09b632839fc2c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_41d7fc3f015642af4dcede4b49f128b5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cd1a6196b51e19811589e80cf69d1abc |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate |
2009-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c1e5caf5a34f88e53dfff2bb5843053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e9d9a61b914eec9fa8f4a8f01a1c69b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e87549bcf41e94d13fce1d8f1bda9c68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f01e066ae0487f2861a80b6c34917155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2bdb4a5434cee489b50d0b8d04b000e |
| publicationDate |
2009-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009318537-A1 |
| titleOfInvention |
Silencing of tgf beta type ii receptor expression by sirna |
| abstract |
The present application is directed to siRNA-based silencing of the type II receptor of TGFβ. siRNAs that target this receptor abrogate the receptor protein and transcript, TGFβ-mediated processes such as fibronectin assembly and cell migration also are inhibited and the molecules of the invention are efficacious in reducing the inflammatory response and matrix deposition. These findings show that siRNAs can be successfully delivered both in vitro and in vivo to regulate the TGFβ type II receptor level and modulate wound response. Methods and compositions exploiting the findings of the present invention have a wide-ranging application, extending from treatment of disorders of the eye to other organs and tissues throughout the body. |
| priorityDate |
2003-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |